Melanocortin-1 receptor agonist
Afamelanotide
An approved implant that increases pain-free light exposure in adults with EPP, not a general-purpose tanning or cosmetic peptide.
Also known as Scenesse · Nle4-D-Phe7-alpha-MSH · melanocortin-1 agonist
01 · Evidence profile
One molecule, four evidence questions
Randomized trials support pain-free light-exposure and quality-of-life outcomes in adults with EPP.
The approved implant's pharmacology and melanocortin-1 activity are characterized.
The label and postauthorization monitoring characterize known risks and skin-monitoring requirements.
High for authentic Scenesse; low for transfer to other melanocortin products.
02 · Identity
What it is
Afamelanotide is an alpha-melanocyte-stimulating hormone analogue and melanocortin-1 receptor agonist delivered in the approved Scenesse implant.
03 · Product identity
The molecule is not the finished product.
Scenesse is a healthcare-professional-administered implant. It is not equivalent to tanning peptides, compounded injections, or other melanocortin analogues.
Scenesse
2024 label- Formulation
- Controlled-release implant
- Route
- Subcutaneous implant administered by a trained professional
- Indication scope
- Increase pain-free light exposure in adults with erythropoietic protoporphyria and a history of phototoxic reactions.
- Scenesse
- Increase pain-free light exposure in adults with erythropoietic protoporphyria
04 · Evidence snapshot
What the evidence can and cannot say
Randomized trials in erythropoietic protoporphyria reported more pain-free light exposure and improvements in disease-specific quality of life. FDA approved Scenesse for a corresponding adult population.
The approval does not establish general tanning, cosmetic anti-aging, athletic, or other disease benefits, and it does not validate different melanocortin peptides.
05 · Claim check
Three claims under the lens
“Afamelanotide increases pain-free light exposure in adults with EPP.”
The label and randomized trials support this defined rare-disease outcome.
- Evidence basis
- Randomized human outcomes
- Scope
- Adults with a history of phototoxic reactions from erythropoietic protoporphyria.
“Scenesse is an approved cosmetic tanning implant.”
Its approval is for pain-free light exposure in adults with EPP, not cosmetic tanning.
- Evidence basis
- Regulatory or product record
- Scope
- The current FDA-approved indication.
“Afamelanotide evidence proves other tanning peptides are safe and effective.”
Different molecules and products require their own identity, quality, safety, and outcome evidence.
- Evidence basis
- Regulatory or product record
- Scope
- Other melanocortin analogues and unapproved products.
06 · Safety boundary
Before this becomes personal
The implant is administered by trained healthcare professionals and the label calls for skin monitoring. This guide provides no implant or cosmetic-use instructions.
This editorial review did not determine sport eligibility. Athletes must check the current prohibited list, Global DRO, and their governing body.
Reviewed 2026-07-23. This status is not personal clearance to compete.07 · Sources
Check the primary record
08 · Provenance
Review history
Initial brief based on the current Scenesse label, pivotal trials, and orphan-drug record.
Responsible editor: Anthony Treviso. Editorial source review completed. This page has not been independently medically reviewed by a physician or pharmacist.